C WorldWide Group Holding A S boosted its stake in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 3.4% during the second quarter, Holdings Channel reports. The firm owned 182,148 shares of the company’s stock after buying an additional 6,030 shares during the period. C WorldWide Group Holding A S’s holdings in Oxford Immunotec Global PLC were worth $3,064,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Quantitative Systematic Strategies LLC purchased a new position in shares of Oxford Immunotec Global PLC during the first quarter valued at about $156,000. Parkwood LLC purchased a new position in shares of Oxford Immunotec Global PLC during the first quarter valued at about $176,000. American International Group Inc. raised its position in shares of Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after buying an additional 904 shares during the period. Nationwide Fund Advisors raised its position in shares of Oxford Immunotec Global PLC by 1.9% in the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock valued at $213,000 after buying an additional 254 shares during the period. Finally, TFS Capital LLC raised its position in shares of Oxford Immunotec Global PLC by 19.8% in the first quarter. TFS Capital LLC now owns 14,125 shares of the company’s stock valued at $219,000 after buying an additional 2,337 shares during the period. 87.03% of the stock is owned by institutional investors.

Oxford Immunotec Global PLC (OXFD) opened at 17.18 on Friday. The firm’s market cap is $396.45 million. The stock has a 50 day moving average of $16.79 and a 200 day moving average of $15.13. Oxford Immunotec Global PLC has a one year low of $9.15 and a one year high of $19.51.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. The company had revenue of $26.10 million during the quarter, compared to analysts’ expectations of $25.05 million. During the same period in the prior year, the company posted ($0.29) earnings per share. Oxford Immunotec Global PLC’s revenue for the quarter was up 35.9% compared to the same quarter last year. Equities research analysts predict that Oxford Immunotec Global PLC will post ($1.65) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Oxford Immunotec Global PLC (OXFD) Shares Bought by C WorldWide Group Holding A S” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/12/oxford-immunotec-global-plc-oxfd-shares-bought-by-c-worldwide-group-holding-a-s.html.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Cowen and Company reissued a “buy” rating and issued a $22.00 price target on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Piper Jaffray Companies reissued a “buy” rating and issued a $26.00 price target on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. ValuEngine raised shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BTIG Research reissued a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Thursday, May 4th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $21.00.

In other news, VP Elizabeth M. Keiley sold 4,085 shares of the stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $15.01, for a total transaction of $61,315.85. Following the completion of the sale, the vice president now directly owns 25,393 shares in the company, valued at $381,148.93. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Peter Wrighton-Smith sold 32,832 shares of the stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $16.58, for a total transaction of $544,354.56. Following the sale, the chief executive officer now owns 478,106 shares of the company’s stock, valued at $7,926,997.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 126,456 shares of company stock valued at $2,063,095. 7.58% of the stock is currently owned by corporate insiders.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.